title: Eosinophilic cellulitis (Wells' syndrome) as a cutaneous reaction to the administration of adalimumab.
authors.forename: P
authors.initials: P
authors.lastname: Boura
authors.forename: A
authors.initials: A
authors.lastname: Sarantopoulos
authors.forename: I
authors.initials: I
authors.lastname: Lefaki
authors.forename: P
authors.initials: P
authors.lastname: Skendros
authors.forename: P
authors.initials: P
authors.lastname: Papadopoulos
mesh_terms: D000068879:Adalimumab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy; D002481:Cellulitis / Q000139:chemically induced*; D004802:Eosinophilia / Q000139:chemically induced*; D005260:Female; D006801:Humans; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab